Hopp til innhold
NHI.no
Annonse

Venøs blodpropp i hjernen: Prognose

Innhold i artikkelen

Ved tidlig diagnose er prognosen god og full restitusjon eller mindre nevrologiske skader kan forventes hos ca. 80 prosent. Ca. 5 prosent dør i akuttfasen og dødeligheten over noe lengre tid er nær 10 prosent. Koma, kramper eller underliggende sykdom har liten innvirkning på korttidsprognosen og bør ikke begrense behandlingstilbudet. På lang sikt vil ca. 2 til 4 prosent kunne få en ny episode med venetrombose.

Annonse

Omtrent 10 prosent av pasientene har vedvarende nevrologiske utfall, som språkproblemer og sensoriske og motoriske symptomer ved ettårsoppfølging. Imidlertid opplever omtrent halvparten av pasientene mer kroniske, ukarakteristiske symptomer som vedvarende hodepine, tretthet, depresjon eller diffuse nevropsykologiske problemer. 

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Cerebral venetrombose . Referanselisten for dette dokumentet vises nedenfor

  1. Kristoffersen ES, Harper CE, Vetvik KG, Faiz KW. Cerebral venous thrombosis - epidemiology, diagnosis and treatment. Cerebral venetrombose – forekomst, diagnostikk og behandling. Tidsskr Nor Laegeforen. 2018;138(12):10.4045/tidsskr.17.1047. Published 2018 Aug 20.
  2. McElveen WA. Cerebral Venous Thrombosis. Medscape, last updated Oct 09, 2018. emedicine.medscape.com
  3. Schwedt TJ, Matharu MS, Dodick DW. Thunderclap Headache. Lancet Neurol 2006; 5: 621-31. PubMed
  4. Ferro JM, Canhão P. Cerebral venous thrombosis: Etiology, clinical features, and diagnosis. UpToDate, last updated Aug 31, 2018. UpToDate
  5. Silvis SM, de Sousa DA, Ferro JM et al. Cerebral venous thrombosis. Nat Rev Neurol 2017; 13: 555 - 65. PubMed
  6. Coutinho JM, Ferro JM, Canhão P, et al. Cerebral venous and sinus thrombosis in women. Stroke 2009; 40:2356. Stroke
  7. Duman T, Uluduz D, Midi I et al. A Multicenter study of 1144 patients with cerebral venous thrombosis: The VENOST Study. J Stroke Cerebrovasc Dis 2017; 26: 1848 - 57. PubMed
  8. Agostoni E. Headache in cerebral venous thrombosis. Neurol Sci 2004; 25 Suppl 3: 206.
  9. Dentali F, Squizzato A, Marchesi C et al. D-dimer testing in the diagnosis of cerebral vein thrombosis: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2012; 10: 582 - 9. PubMed
  10. Linn J, Ertl-Wagner B, Seelos KC, Strupp M, Reiser M, Brückmann H, Brüning R. Diagnostic value of multidetector-row CT angiography in the evaluation of thrombosis of the cerebral venous sinuses. Am J Neuroradiol 2007; 28: 946-52. PubMed
  11. Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med. 2015. PMID: 26095467 PubMed
  12. Ferro JM, Canhão M. Cerebral venous thrombosis: Treatment and prognosis. UpToDate, last updated Apr 06, 2022. UpToDate
  13. Ferro JM, Bousser MG, Canhão P et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol 2017; 24: 1203 - 13. PubMed
  14. Coutinho JM, Stam J. How to treat cerebral venous and sinus thrombosis. J Thromb Haemost 2010; 8:877. PubMed
  15. Coutinho J, de Bruijn SFTM, deVeber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No.: CD002005. DOI: 10.1002/14651858.CD002005.pub2. DOI
  16. Al Rawahi B, Almegren M, Carrier M. The efficacy and safety of anticoagulation in cerebral vein thrombosis: A systematic review and meta-analysis. Thromb Res. 2018 Sep;169:135-139. pmid:30056293 PubMed
  17. Liberman AL. Diagnosis and Treatment of Cerebral Venous Thrombosis. Continuum (Minneap Minn). 2023;29(2):519-539. PMID:37039408. PubMed
  18. Viegas LD, Stolz E, Canhão P et al. Systemic thrombolysis for cerebral venous and dural sinus thrombosis: a systematic review. Cerebrovasc Dis 2014; 37: 43 - 50. PubMed
  19. Hiltunen S, Putaala J, Haapaniemi E et al. Long-term outcome after cerebral venous thrombosis: analysis of functional and vocational outcome, residual symptoms, and adverse events in 161 patients. J Neurol 2016; 263: 477 - 84. PubMed
Annonse
Annonse